查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1225463

Duchenne肌營養不良症治療市場：按產品類型（皮質類固醇,疼痛管理劑）,治療方法（突變抑制,外顯子跳躍,類固醇治療）,用戶（醫院,診所,家庭護理環境）地區2023-2028

Duchenne Muscular Dystrophy Drugs Market by Product Type (Corticosteroids, Pain Management Drugs), Therapeutic Approach (Mutation Suppression, Exon Skipping, Steroid Therapy), End User (Hospitals, Clinics, Home Care Settings), and Region 2023-2028
出版日期: | 出版商: IMARC | 英文 143 Pages | 商品交期: 2-3個工作天內

價格

市場概覽

  • 到 2022 年，杜氏肌營養不良症的全球市場將達到 20.4 億美元。 展望未來，IMARC Group 預測到 2028 年將達到 40 億美元，顯示 2023 年至 2028 年之間的增長率 (CAGR) 為 11.41%。 Duchenne 肌營養不良症在公眾中的患病率上升,新產品批准和推出的數量增加,政府努力提供有利的報銷政策以及推廣靶向特異性療法是推動市場的一些主要驅動力
  • 杜興氏肌營養不良症 (DMD) 藥物用於治療主要影響男性且很少影響女性的進行性,嚴重的 X 連鎖遺傳性肌營養不良症。 該疾病的症狀包括行走,站立和坐姿困難,言語問題以及進行性無力和稱為萎縮的骨骼肌和心肌喪失。 DMD 藥物靶向心臟和骨骼肌，以改善患者的心肺健康。 抗肌萎縮蛋白是維持肌肉的重要蛋白質，其缺乏或異常會引起DMD。 因此，許多 DMD 藥物靶向抗肌萎縮蛋白。 與恢復抗肌萎縮蛋白產生,膜穩定或代償蛋白上調,炎症級聯反應減少和/或促進肌肉再生的特定突變相關的基因治療也是 DMD 主要治療策略的一部分。它是

杜氏肌營養不良症治療藥物的市場趨勢

  • 主要製造商批准和推出新產品的數量增加已成為推動市場增長的重要因素。 這歸因於公眾中 Duchenne 肌營養不良症的發病率不斷增加。 與此同時，臨床試驗的顯著增加和強大產品線的存在正在為市場增添動力。 此外，導致突變特異性療法出現的診斷技術不斷創新也對市場產生了積極影響。 此外，廣泛的研發活動也推動了市場的發展，這些研發活動專注於為嬰兒,婦女和行動不便的患者等服務不足的患者準確診斷和治療 DMD 。 然而，缺乏驗證藥物臨床療效的標準化程序,診斷和預測的延誤以及基因治療藥物成本的上升正在成為市場增長的製約因素。 另一方面，政府積極努力提供有利的報銷政策和促進有針對性的治療正在促進市場的增長。 其他因素，如快速城市化,改善醫療基礎設施,產品可擴展性趨勢以及大眾可支配收入增加，正在為市場帶來有利可圖的增長機會。

主要市場細分

  • IMARC Group 分析了全球杜氏肌營養不良症治療市場每個細分市場的主要趨勢，並預測了 2023 年至 2028 年在全球,區域和國家層面的情況。 該報告根據產品類型,治療方法和最終用戶對市場進行分類。

產品類型洞察

  • 腎上腺皮質激素（皮質類固醇）
  • 潑尼松龍
  • 潑尼松
  • 氟氮唑
  • 止痛藥
  • 本報告按產品類型對杜氏肌營養不良症治療市場進行了詳細細分和分析。 這包括皮質類固醇（潑尼松龍,潑尼松,地夫可特）和止痛藥物。 皮質類固醇佔最大部分。

對治療方法的見解

  • 突變抑制
  • 外顯子跳躍
  • 類固醇療法
  • 本報告根據治療方法對杜氏肌營養不良症治療市場進行了深入細分和分析。 這包括突變抑制,外顯子跳躍和類固醇治療。 外顯子跳躍佔最大部分。

最終用戶洞察

  • 醫院
  • 醫務室
  • 家庭保健設置
  • 該報告還根據最終用戶對杜氏肌營養不良症治療市場進行了深入分類和分析。 這包括醫院,診所和家庭護理場所。 醫院佔據了最大的市場份額。

地理洞察

  • 北美
  • 美國
  • 加拿大
  • 亞太地區
  • 中國
  • 日本
  • 印度
  • 韓國
  • 澳大利亞
  • 印度尼西亞
  • 其他
  • 歐洲
  • 德國
  • 法國
  • 英國
  • 意大利
  • 西班牙
  • 俄羅斯
  • 其他
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 其他
  • 中東和非洲
  • 北美（美國,加拿大）,亞太地區（中國,日本,印度,韓國,澳大利亞,印度尼西亞等）,歐洲（德國,法國,英國,意大利,西班牙,俄羅斯等） ,拉丁美洲（巴西）,墨西哥等）以及中東和非洲進行了綜合分析。 另外，北美是杜氏肌營養不良症的最大市場。 推動北美 Duchenne 肌營養不良症治療市場的因素包括新產品批准和發布數量的增加,醫療基礎設施的持續改善以及多個主要參與者的存在。

本報告中回答的關鍵問題

  • 到目前為止，杜氏肌營養不良症治療藥物的全球市場發生了怎樣的變化，未來幾年又將發生怎樣的變化？
  • 全球杜氏肌營養不良症治療市場的驅動因素,制約因素和機遇是什麼？
  • 主要的區域市場是什麼？
  • 哪些國家/地區代表了最具吸引力的杜氏肌營養不良症藥物市場？
  • 按產品類型劃分的市場細分情況如何？
  • 按治療方法劃分的市場細分情況如何？
  • 最終用戶的市場細分情況如何？
  • 全球杜氏肌營養不良藥物市場的競爭結構如何？
  • 全球杜氏肌營養不良症治療市場的主要參與者/公司在哪裡？

內容

第1章前言

第 2 章研究方法和範圍

  • 調查的目的
  • 利益相關者
  • 數據來源
    • 主要信息
    • 次要信息
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章執行摘要

第4章介紹

  • 概覽
  • 主要行業趨勢

第 5 章杜氏肌營養不良症藥物的全球市場

  • 市場概覽
  • 市場結果
  • COVID-19 的影響
  • 市場預測

第 6 章按產品類型劃分的市場細分

  • 皮質類固醇
    • 市場趨勢
    • 主要細分市場
      • 潑尼松龍
      • 潑尼松
      • Defraza Colt
    • 市場預測
  • 止痛藥
    • 市場趨勢
    • 市場預測

第 7 章按處理方法劃分的市場細分

  • 突變抑制
    • 市場趨勢
    • 市場預測
  • 外顯子跳躍
    • 市場趨勢
    • 市場預測
  • 類固醇療法
    • 市場趨勢
    • 市場預測

第 8 章最終用戶市場細分

  • 醫院
    • 市場趨勢
    • 市場預測
  • 醫務室
    • 市場趨勢
    • 市場預測
  • 家庭醫療
    • 市場趨勢
    • 市場預測

第 9 章按區域劃分的市場細分

  • 北美
    • 美國
      • 市場趨勢
      • 市場預測
    • 加拿大
      • 市場趨勢
      • 市場展望
  • 亞太地區
    • 中國
      • 市場趨勢
      • 市場展望
    • 日本
      • 市場趨勢
      • 市場展望
    • 印度
      • 市場趨勢
      • 市場展望
    • 韓國市場
      • 市場趨勢
      • 市場展望
    • 澳大利亞
      • 市場趨勢
      • 市場展望
    • 印度尼西亞
      • 市場趨勢
      • 市場展望
    • 其他
      • 市場趨勢
      • 市場預測
  • 歐洲
    • 德國
      • 市場趨勢
      • 市場展望
    • 法國
      • 市場趨勢
      • 市場預測
    • 英國
      • 市場趨勢
      • 市場預測
    • 意大利
      • 市場趨勢
      • 市場展望
    • 西班牙
      • 市場趨勢
      • 市場展望
    • 俄羅斯
      • 市場趨勢
      • 市場展望
    • 其他
      • 市場趨勢
      • 市場預測
  • 拉丁美洲
    • 巴西
      • 市場趨勢
      • 市場展望
    • 墨西哥
      • 市場趨勢
      • 市場展望
    • 其他
      • 市場趨勢
      • 市場預測
  • 中東和非洲
    • 市場趨勢
    • 按國家/地區劃分的市場細分
    • 市場預測

第 10 章：驅動因素,制約因素和機遇

  • 概覽
  • 司機
  • 抑製劑條件
  • 商機

第11章價值鏈分析

第12章搬運工五力分析

  • 概覽
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章競爭格局

  • 市場結構
  • 主要公司
  • 主要公司簡介
    • FibroGen Inc.
    • Italfarmaco S.p.A.
    • NS Pharma Inc.（Nippon Shinyaku Co. Ltd.）
    • PTC Therapeutics Inc.
    • Santhera Pharmaceuticals
    • Sarepta Therapeutics Inc.

本報告所列公司僅為部分，所有公司名稱均包含在本報告中。

Product Code: SR1423A304_Report

Market Overview:

  • The global Duchenne muscular dystrophy drugs market size reached US$ 2.04 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.00 Billion by 2028, exhibiting a growth rate (CAGR) of 11.41% during 2023-2028. The rising prevalence of Duchenne muscular dystrophy among the masses, the increasing number of new product approvals and launches, and favorable government initiatives providing good reimbursement policies, along with promoting target-specific treatments, represent some of the key factors driving the market.
  • Duchenne muscular dystrophy (DMD) drugs are utilized to treat a severe X-linked genetic disorder of a progressive form of muscular dystrophy that primarily affects the male population, and rarely females as well. The symptoms of this disorder include difficulty walking, standing, and sitting, as well as speech difficulties, which can result in progressive weakness and loss, also known as atrophy, in the skeletal and heart muscles. The DMD drugs enhance cardiac and pulmonary functions in patients by targeting cardiac and skeletal muscles. Dystrophin is a key protein that maintains muscular integrity, and its absence or abnormality causes DMD. As a result, most of the drugs for the treatment of DMD are dystrophin-based. Some of the other primary treatment strategies for DMD also include genetic therapies linked to specific mutations which restore dystrophin production, membrane stabilization or upregulation of compensatory proteins, and a reduction of the inflammatory cascade and/or enhancement of muscle regeneration.

Duchenne Muscular Dystrophy Drugs Market Trends:

  • The rising number of new product approvals and launches by the major manufacturers is a significant factor driving the growth of the market. This can be attributed to the growing incidences of Duchenne muscular dystrophy among the masses. In line with this, a considerable rise in clinical trials, along with the presence of strong pipeline of products, is providing an impetus to the market. Moreover, the advent of mutation-specific therapies due to continual innovations in diagnostics is also impacting the market positively. Besides this, extensive research and development (R&D) activities focusing on accurate diagnosis and treatment of DMD for underserved categories, such as infants, females, and nonambulant patients, are propelling the market. However, the shortage of standardized procedures for the examination of the clinical efficacy of drugs, delayed diagnosis and prediction, and the rising costs of genetic therapeutics are acting as growth-restraining factors for the market. On the contrary, favorable government initiatives providing good reimbursement policies, along with promoting target-specific treatments, are contributing to the market growth. Some of the other factors creating lucrative growth opportunities in the market include rapid urbanization, improving medical infrastructure, emerging trend of product premiumization, and inflating disposable incomes of the masses.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each segment of the global Duchenne muscular dystrophy drugs market, along with forecasts at the global, regional, and country level from 2023-2028. Our report has categorized the market based on product type, therapeutic approach, and end user.

Product Type Insights:

  • Corticosteroids
  • Prednisolone
  • Prednisone
  • Deflazacort
  • Pain Management Drugs
  • The report has provided a detailed breakup and analysis of the Duchenne muscular dystrophy drugs market based on the product type. This includes corticosteroids (prednisolone, prednisone and deflazacort) and pain management drugs. According to the report, corticosteroids represented the largest segment.

Therapeutic Approach Insights:

  • Mutation Suppression
  • Exon Skipping
  • Steroid Therapy
  • The report has provided a detailed breakup and analysis of the Duchenne muscular dystrophy drugs market based on the therapeutic approach. This includes mutation suppression, exon skipping, and steroid therapy. According to the report, exon skipping represented the largest segment.

End User Insights:

  • Hospitals
  • Clinics
  • Home Care Settings
  • A detailed breakup and analysis of the Duchenne muscular dystrophy drugs market based on the end user has also been provided in the report. This includes hospitals, clinics, and home care settings. According to the report, hospitals accounted for the largest market share.

Regional Insights:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
  • The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for Duchenne muscular dystrophy drugs. Some of the factors driving the North America Duchenne muscular dystrophy drugs market include the rising number of new product approvals and launches, continual improvements in medical infrastructure, and the presence of several key players in the country.

Competitive Landscape:

  • The report has also provided a comprehensive analysis of the competitive landscape in the global Duchenne muscular dystrophy drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include FibroGen Inc., Italfarmaco S.p.A., NS Pharma Inc. (Nippon Shinyaku Co. Ltd.), PTC Therapeutics Inc., Santhera Pharmaceuticals, Sarepta Therapeutics Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global Duchenne muscular dystrophy drugs market performed so far and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global Duchenne muscular dystrophy drugs market?
  • What are the key regional markets?
  • Which countries represent the most attractive Duchenne muscular dystrophy drugs markets?
  • What is the breakup of the market based on the product type?
  • What is the breakup of the market based on the therapeutic approach?
  • What is the breakup of the market based on end user?
  • What is the competitive structure of the global Duchenne muscular dystrophy drugs market?
  • Who are the key players/companies in the global Duchenne muscular dystrophy drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Duchenne Muscular Dystrophy Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Corticosteroids
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Prednisolone
      • 6.1.2.2 Prednisone
      • 6.1.2.3 Deflazacort
    • 6.1.3 Market Forecast
  • 6.2 Pain Management Drugs
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Therapeutic Approach

  • 7.1 Mutation Suppression
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Exon Skipping
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Steroid Therapy
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Home Care Settings
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 FibroGen Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 Italfarmaco S.p.A.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 NS Pharma Inc. (Nippon Shinyaku Co. Ltd.)
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 PTC Therapeutics Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Santhera Pharmaceuticals
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Sarepta Therapeutics Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

  • Figure 1: Global: Duchenne Muscular Dystrophy Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by Product Type (in %), 2022
  • Figure 5: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by Therapeutic Approach (in %), 2022
  • Figure 6: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by End User (in %), 2022
  • Figure 7: Global: Duchenne Muscular Dystrophy Drugs Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Duchenne Muscular Dystrophy Drugs (Corticosteroids) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Duchenne Muscular Dystrophy Drugs (Corticosteroids) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Duchenne Muscular Dystrophy Drugs (Pain Management Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Duchenne Muscular Dystrophy Drugs (Pain Management Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Duchenne Muscular Dystrophy Drugs (Mutation Suppression) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Duchenne Muscular Dystrophy Drugs (Mutation Suppression) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Duchenne Muscular Dystrophy Drugs (Exon Skipping) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Duchenne Muscular Dystrophy Drugs (Exon Skipping) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Duchenne Muscular Dystrophy Drugs (Steroid Therapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Duchenne Muscular Dystrophy Drugs (Steroid Therapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Duchenne Muscular Dystrophy Drugs (Hospitals) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Duchenne Muscular Dystrophy Drugs (Hospitals) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Duchenne Muscular Dystrophy Drugs (Clinics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Duchenne Muscular Dystrophy Drugs (Clinics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Duchenne Muscular Dystrophy Drugs (Home Care Settings) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Duchenne Muscular Dystrophy Drugs (Home Care Settings) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: North America: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: North America: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: United States: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: United States: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: Canada: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: Canada: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: Asia-Pacific: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: Asia-Pacific: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: China: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: China: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: Japan: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: Japan: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: India: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: India: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: South Korea: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: South Korea: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: Australia: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: Australia: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: Indonesia: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: Indonesia: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Others: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Others: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: Europe: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: Europe: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: Germany: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: Germany: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: France: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: France: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: United Kingdom: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: United Kingdom: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: Italy: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: Italy: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Spain: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Spain: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Russia: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Russia: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: Others: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: Others: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: Latin America: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: Latin America: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Brazil: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Brazil: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Mexico: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Mexico: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Others: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Others: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Middle East and Africa: Duchenne Muscular Dystrophy Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Middle East and Africa: Duchenne Muscular Dystrophy Drugs Market: Breakup by Country (in %), 2022
  • Figure 72: Middle East and Africa: Duchenne Muscular Dystrophy Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 73: Global: Duchenne Muscular Dystrophy Drugs Industry: Drivers, Restraints, and Opportunities
  • Figure 74: Global: Duchenne Muscular Dystrophy Drugs Industry: Value Chain Analysis
  • Figure 75: Global: Duchenne Muscular Dystrophy Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Duchenne Muscular Dystrophy Drugs Market: Key Industry Highlights, 2022 & 2028
  • Table 2: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Breakup by Product Type (in Million US$), 2023-2028
  • Table 3: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Breakup by Therapeutic Approach (in Million US$), 2023-2028
  • Table 4: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Breakup by End User (in Million US$), 2023-2028
  • Table 5: Global: Duchenne Muscular Dystrophy Drugs Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Duchenne Muscular Dystrophy Drugs Market: Competitive Structure
  • Table 7: Global: Duchenne Muscular Dystrophy Drugs Market: Key Players